Plasmapheresis for Treatment of Light Chain Amyloidosis Related Myopathy

Can J Neurol Sci. 2024 May;51(3):432-434. doi: 10.1017/cjn.2023.38. Epub 2023 Apr 3.

Tefani Perera¹, Shahin Khayambashi², Gordon Jewett^{1

3}, Christopher Hahn¹, Sylvia McCulloch^{4

5}, Jeffrey T Joseph^{3

6}, Sameer Chhibber¹

¹ Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
² Department of Internal Medicine, Division of Neurology, University of British Columbia, Vancouver, BC, Canada.
³ Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
⁴ Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
⁵ Tom Baker Cancer Centre, CalgaryAB, Canada.
⁶ Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

No abstract available

Keywords: Amyloid myopathy; Immunoglobulin light chain amyloidosis; Light chain amyloid associated myopathy; Light chain multiple myeloma.

Publication types